Antibodies against Helicobacter felis in sera of cats and dogs.

Serum samples from 61 dogs and 49 cats were screened for circulating antibodies against Helicobacter felis by an enzyme-linked immunosorbent assay (ELISA) using sonicated bacteria as an antigen. To improve the specificity of the ELISA, sera were absorbed with Campylobacter jejuni subsp. jejuni H. pylori as well as H. felis. Sera from 26 dogs (43%) and 19 cats (39%) revealed clear positive absorbance readings determined as an optical density (OD) that was statistically significant above the OD mean value [P < 0.025 (one-tailed); log10]. The absorbance pattern of ELISA-positive sera corresponded to results obtained with bovine and human reference sera. Furthermore, a correlation between the immune response and results from histopathological examination of gastric specimens from 22 dogs was demonstrated. It could be shown that antibodies against H. felis in sera of cats and dogs can easily be detected using an ELISA. The diagnostic value of this test must be evaluated in further investigations.     

Efficacy Of Cythioate Against Fleas On Dogs And Cats

Abstract— -The efficacy of cythioate (O,O-dimethyl-O-p-sulphamoylphenyl phosphorothioate) against Ctenocephalides spp was investigated in two controlled field trials involving 12 dogs and 11 cats, respectively. At a dose-rate of 3 mg kg^-1, the flea population of greyhounds heavily infected with Ct. canis and Ct.felis was reduced by over 95 per cent, while an efficacy figure in excess of 90 per cent was recorded against Ct. felis in lightly infected cats treated at 1.5 mg kg^-1.
Résumé— L'efficacité du cythioate (O,O-dimethyl-O-p-sulphamoyl-phenyl phosphorothioate) contre Ctenocephalides spp a étéévaluée dans deux expérimentations controlées par rapport à des lots témoins et portant respectivement sur 12 chiens et 11 chats. Pour une dose moyenne de 3 mg Kg^-1, la population des puces sur des Greyhounds lourdement infestés par Ct. canis et Ct.felis fut réduite de plus de 95%, cependant qu'un taux d'efficacité supérieur à 90% fut constaté contre Ct. felis sur des chats légèrement infestés, à la dose de 1.5 mg Kg^-1.
Zusammenfassung— Die Wirksamkeit von Zythioath (O,O-dimethyl-O-p-sulphamoylphenyl phosphorothioate) gegen Ctenocephalides spp. wurde in zwei kontrollierten Feldversuchen an 12 Hunden und 11 Katzen geprüft. Bei einer Dosis von 3 mg/kg wurde die Flohpopulation von Greyhounds, die mit Ct. canis und Ct. felis massiv infiziert waren, über 95% reduziert. Bei leicht infizierten Katzen, die mit 1.5 mg/kg behandelt wurden, lag die Wirksamkeit gegen Ct. felis bei über 90%.     

Efficacy Of Cythioate Against Fleas On Dogs And Cats

Abstract— -The efficacy of cythioate (O,O-dimethyl-O-p-sulphamoylphenyl phosphorothioate) against Ctenocephalides spp was investigated in two controlled field trials involving 12 dogs and 11 cats, respectively. At a dose-rate of 3 mg kg^-1, the flea population of greyhounds heavily infected with Ct. canis and Ct.felis was reduced by over 95 per cent, while an efficacy figure in excess of 90 per cent was recorded against Ct. felis in lightly infected cats treated at 1.5 mg kg^-1. Résumé— L'efficacité du cythioate (O,O-dimethyl-O-p-sulphamoyl-phenyl phosphorothioate) contre Ctenocephalides spp a étéévaluée dans deux expérimentations controlées par rapport à des lots témoins et portant respectivement sur 12 chiens et 11 chats. Pour une dose moyenne de 3 mg Kg^-1, la population des puces sur des Greyhounds lourdement infestés par Ct. canis et Ct.felis fut réduite de plus de 95%, cependant qu'un taux d'efficacité supérieur à 90% fut constaté contre Ct. felis sur des chats légèrement infestés, à la dose de 1.5 mg Kg^-1. Zusammenfassung— Die Wirksamkeit von Zythioath (O,O-dimethyl-O-p-sulphamoylphenyl phosphorothioate) gegen Ctenocephalides spp. wurde in zwei kontrollierten Feldversuchen an 12 Hunden und 11 Katzen geprüft. Bei einer Dosis von 3 mg/kg wurde die Flohpopulation von Greyhounds, die mit Ct. canis und Ct. felis massiv infiziert waren, über 95% reduziert. Bei leicht infizierten Katzen, die mit 1.5 mg/kg behandelt wurden, lag die Wirksamkeit gegen Ct. felis bei über 90%.     

Evidence of Anti-Gliadin and Transglutaminase Antibodies in Sera of Dogs Affected by Lymphoplasmacytic Enteritis

Veterinary Research Communications -     

新疆地区牛新孢子虫病血清抗体检测及结果分析

为了解新疆地区牛新孢子虫病的流行情况,用ELISA方法对采自新疆6个地区327份的牛血清进行了新孢子虫病的抗体检测,并以第一次检测结果为依据,对20头牛进行了5次连续采样检测,每次间隔30～40天。检测结果表明,该病在新疆不同地区都有不同程度的发生和流行,平均阳性率为24.5%,且在年龄大和流产牛群中阳性率偏高,血清抗体阳性持续时间至少半年以上。     

Cardiac Troponins in Dogs and Cats

Cardiac troponins are sensitive and specific markers of myocardial injury. The troponin concentration can be thought of as a quantitative measure of the degree of injury sustained by the heart, however, it provides no information on the cause of injury or the mechanism of troponin release. Conventionally, the cardiac troponins have been used for diagnosis of acute myocardial infarction in humans and have become the gold standard biomarkers for this indication. They have become increasingly recognized as an objective measure of cardiomyocyte status in both cardiac and noncardiac disease, supplying additional information to that provided by echocardiography and ECG. Injury to cardiomyocytes can occur through a variety of mechanisms with subsequent release of troponins. Independent of the underlying disease or the mechanism of troponin release, the presence of myocardial injury is associated with an increased risk of death. As increasingly sensitive assays are introduced, the frequent occurrence of myocardial injury is becoming apparent, and our understanding of its causes and importance is constantly evolving. Presently troponins are valuable for detecting a subgroup of patients with higher risk of death. Future research is needed to clarify whether troponins can serve as monitoring tools guiding treatment, whether administering more aggressive treatment to patients with evidence of myocardial injury is beneficial, and whether normalizing of troponin concentrations in patients presenting with evidence of myocardial injury is associated with reduced risk of death.     

Renal Ultrasound in Dogs and Cats

Veterinary Research Communications -     

Thrombolytic Therapy in Dogs and Cats

Objective: To review the thrombolytic agents most commonly used in humans, their mechanisms of action, potential uses, adverse effects, and reports of their use in dogs and cats.
Human data synthesis: Thrombolytic agents avaliable in human medicine include streptokinase, urokinase, tissueplasminogen activator (t-PA), single-chain urokinase plasma activator (scu-PA) and anisoylated plasminogen-strep-tokinase activator complex (APSAC). These agents were originally used for the management of proximal deep vein thrombosis and severe pulmonary embolism but more recently, use of these drugs has been extended to include the treatment of acute peripheral arterial disease, cerebrovascular disease (stroke) and acute coronary thrombosis. The most predictable side effect associated with the use of thrombolytic therapy is hemorrhage.
Veterinary data synthesis: Clinical experience with thrombolytic agents in small animals is limited to streptokinase and t-PA. It is possible, that as in humans, canine and feline patients with PTE and right ventricular dysfunction may benefit from thrombolytic therapy but there are no veterinary studies to support this theory to date. Successful use of streptokinase has been documented in a small number of canine patients with systemic thromboembolism. ⁶³ Thrombolytic therapy is relatively efficacious in cats with aortic thromboemboli but is associated with a high mortality rate. ^59,60,64 With regard to use of t-PA in veterinary medicine, the small number of animals treated with varying protocols makes it impossible to provide safe and effective dose recommendations at this time.
Conclusions: Future goals for thrombolytic therapy in veterinary medicine include determination of more specific clinical indications, as well as design of effective protocols that minimize mortality and morbidity.